Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS107 in Advanced Solid Tumors
NCT05502393Phase 1Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JS107 in solid tumor (advanced stage) (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 12 months and Recommended Phase 2 Dose at 24 months. Started Jul 2022; status: active, not recruiting.
02
Drugs
JS107
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05502393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502393.